Patents by Inventor DAVID KAI YUEN POON
DAVID KAI YUEN POON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210277150Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: November 30, 2020Publication date: September 9, 2021Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon, Igor D'Angelo
-
Publication number: 20210009659Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: ApplicationFiled: June 10, 2020Publication date: January 14, 2021Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
-
Patent number: 10875931Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: January 18, 2017Date of Patent: December 29, 2020Assignee: ZYMEWORKS, INC.Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 10711051Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: GrantFiled: November 5, 2018Date of Patent: July 14, 2020Assignee: ZYMEWORKS INC.Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20200087414Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: September 12, 2019Publication date: March 19, 2020Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 10457742Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: January 20, 2017Date of Patent: October 29, 2019Assignee: ZYMEWORKS INC.Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Publication number: 20190127443Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: ApplicationFiled: November 5, 2018Publication date: May 2, 2019Inventors: Surjit Bhimarao DIXIT, Igor Edmondo Paolo D'ANGELO, David Kai Yuen POON
-
Patent number: 10155803Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: GrantFiled: November 17, 2016Date of Patent: December 18, 2018Assignee: ZYMEWORKS INC.Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20180194860Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: January 18, 2017Publication date: July 12, 2018Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
-
Publication number: 20180016347Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: January 20, 2017Publication date: January 18, 2018Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Publication number: 20170174745Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: ApplicationFiled: November 17, 2016Publication date: June 22, 2017Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'ANGELO, David Kai Yuen POON
-
Patent number: 9574010Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: November 2, 2012Date of Patent: February 21, 2017Assignee: Zymeworks Inc.Inventors: Thomas Spreter Von Kreudenstein, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 9562109Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: GrantFiled: November 4, 2011Date of Patent: February 7, 2017Assignee: Zymeworks Inc.Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
-
Patent number: 9499605Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: GrantFiled: March 2, 2012Date of Patent: November 22, 2016Assignee: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20160257763Abstract: Provided herein are isolated heteromultimers comprising: at least one single domain antigen-binding construct attached to at least one monomer of a heterodimer Fc region; wherein the heterodimer Fc region comprises a variant CH3 domain comprising amino acid mutations that promote the formation of said heterodimer with stability comparable to that of a native Fc homodimer; and wherein said isolated heteromultimer is devoid of immunoglobulin light chains and optionally devoid of immunoglobulin CH1 region. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: January 6, 2016Publication date: September 8, 2016Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera, Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
-
Publication number: 20130336973Abstract: Provided herein are isolated heteromultimers comprising: at least one single domain antigen-binding construct attached to at least one monomer of a heterodimer Fc region; wherein the heterodimer Fc region comprises a variant CH3 domain comprising amino acid mutations that promote the formation of said heterodimer with stability comparable to that of a native Fc homodimer; and wherein said isolated heteromultimer is devoid of immunoglobulin light chains and optionally devoid of immunoglobulin CH1 region. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: May 10, 2013Publication date: December 19, 2013Inventors: Thomas SPRETER VON KREUDENSTEIN, Eric ESCOBAR-CABRERA, Gordon Yiu Kon NG, Surjit Bhimarao DIXIT, Paula Irene LARIO, David Kai Yuen POON, Igor Edmondo Paolo D'ANGELO
-
Publication number: 20120244577Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: ApplicationFiled: March 2, 2012Publication date: September 27, 2012Applicant: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20120149876Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.Type: ApplicationFiled: November 4, 2011Publication date: June 14, 2012Applicant: ZYMEWORKS INC.Inventors: THOMAS SPRETER VON KREUDENSTEIN, ERIC ESCOBAR CABRERA, SURJIT BHIMARAO DIXIT, PAULA IRENE LARIO, DAVID KAI YUEN POON, IGOR EDMONDO PAOLO D'ANGELO